Exelixis
EXEL
#1574
Rank
A$17.43 B
Marketcap
$62.30
Share price
2.76%
Change (1 day)
84.77%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of December 2024 : A$3.61 Billion

According to Exelixis's latest financial reports the company has A$3.61 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$A$3.32 B-9.13%
2022-12-31$A$3.65 B19.92%
2021-12-31$A$3.04 B24.77%
2020-12-31$A$2.44 B1.48%
2019-12-31$A$2.40 B31.76%
2018-12-31$A$1.82 B400.69%
2017-12-31$A$0.36 B194.57%
2016-12-31$A$0.12 B-164.11%
2015-12-31$-A$0.2 Billion37.76%
2014-12-31$-A$0.15 Billion-288.95%
2013-12-31$A$74.25 M-73.97%
2012-12-31$A$0.28 B222.71%
2011-12-31$A$88.39 M-139.32%
2010-12-31$-A$0.23 Billion23.33%
2009-12-31$-A$0.19 Billion128.55%
2008-12-31$-A$79.75 Million-181.53%
2007-12-31$A$97.8 M-14.91%
2006-12-31$A$0.11 B46.79%
2005-12-31$A$78.3 M19.59%
2004-12-31$A$65.47 M-69.86%
2003-12-31$A$0.21 B-30.42%
2002-12-31$A$0.31 B-32.82%
2001-12-31$A$0.46 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
A$28.99 B 702.27%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$130.45 B 3,510.16%๐Ÿ‡ซ๐Ÿ‡ท France
A$71.75 B 1,885.56%๐Ÿ‡บ๐Ÿ‡ธ USA
A$26.38 B 630.24%๐Ÿ‡บ๐Ÿ‡ธ USA
A$9.46 B 161.88%๐Ÿ‡บ๐Ÿ‡ธ USA
A$115.11 B 3,085.54%๐Ÿ‡บ๐Ÿ‡ธ USA
A$149.03 B 4,024.32%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$14.07 Million-100.39%๐Ÿ‡บ๐Ÿ‡ธ USA
A$46.44 M-98.71%๐Ÿ‡บ๐Ÿ‡ธ USA